Prolonged survival in epithelial ovarian cancer patients: Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy

Objective: To investigate the effects of Cytoreductive surgery (CRS) combined with Hyperthermic intraperitoneal chemotherapy (HIPEC) on the clinical efficacy and safety of Epithelial ovarian cancer (EOC) patients. Methods: We selected 120 EOC patients treated in the Affiliated Cancer Hospital of Guangzhou Medical University during July 2010 to July 2020 as retrospective case-control study subjects. They were divided into 60 cases in the observation group (CRS and HIPEC) and 60 cases in the comparison group (CRS) according to the principle of balanced clinicopathological characteristics. Adverse effects and prognosis-related factors, Overall survival (OS) and safety were analyzed in the two groups. Results: The results of multifactorial Cox regression analysis showed that CC score [P = 0.013, HR (95%CI) = 2.153 (1.014−7.638)], postoperative chemotherapy cycle [P = 0.045, HR (95%CI) = 2.056 (2.004−6.730)], and treatment method [P = 0.025, HR (95%CI) = 2.409 (1.000−5.814)], lymph node status P = 0.019, [HR (95%CI) = 1.221 (1.032−10.136)], and ascites volume P = 0.034, [HR (95%CI) = 2.459 (1.072−5.643)] were independent influences on overall survival. Conclusions: CRS and HIPEC prolonged overall survival in patients with recurrent EOC with a high safety profile.